|Indications:||Treatment of bronchial asthma and pulmonary disease with spastic bronchial component.|
|Dosage & Administration:||Tablet: Adults: 1 tab 2 or 3 times daily or as prescribed by a physician.
Elderly: ½ tab 2 or 3 times daily.
Syrup: Children >12 years: 1 measuring cup x 10 mL, 2 or 3 times daily; <12 years: 6-9 mg/kg twice daily.
Elderly: 1 measuring cup x 10 mL, 2 or 3 times daily.
|Contraindications:||Individuals who have shown hypersensitivity to Ansimar and its components. Patients with acute myocardial infarction and hypotension.
Use in lactation: Doxofylline is contraindicated in nursing mothers.
|Special Precautions:||The t½ of xanthine derivatives is influenced by a number of known variables. It may be prolonged in patients with liver disease, in patients with congestive heart failure (CHF), in those affected with chronic obstructive lung disease or concomitant infections and in those patients taking certain other drugs (erythromycin, troleandomycin, lincomycin and other antibiotics of the same group, allopurinol, cimetidine, propranolol and anti-flu vaccine). In these cases, a lower dose of doxofylline may be needed. Phenytoin, other anticonvulsants and smoking may cause an increase in clearance with a shorter mean t½. In these cases, higher doses of doxofylline may be needed.
Use with caution in patients with hypoxemia, hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer and in elderly. Frequently, patients with CHF have markedly prolonged drug serum levels following discontinuation of Ansimar.
Use in pregnancy: Animal reproduction studies indicate that doxofylline does not cause fetal harm when administered to pregnant animals nor can affect reproduction capacity. However, since there is limited experience in humans during pregnancy, xanthines should be given to a pregnant woman only if clearly needed.
|Adverse Reactions:||After xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the 1st sign of an intoxication.
Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician.
|Drug Interactions:||Doxofylline should not be administered together with other xanthine derivatives, including beverages and foods containing caffeine.
Toxic synergism with ephedrine has been documented for xanthines.
Concomitant therapy with erythromycin, troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, propranolol and anti-flu vaccine may decrease the hepatic clearance of xanthines causing an increase in blood levels.
|Storage:||Store at room temperature not exceeding 25°C.|
|Mechanism of Action:||Bronchodilator|
|Therapeutic Category:||Antiasthmatic & COPD Preparations|
|ATC Classification:||R03DA11 – doxofylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway diseases.|
|Presentation/Packing:||Tab 200 mg x 30’s, 50’s. 400 mg x 30’s, 50’s. Syrup 100 mg/5 mL x 100 mL|